Faculty
Trevor Jolly, MBBS*
Assistant Professor of Medicine, Division of Oncology
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Jacquelyne Gaddy, MD*
Fellow, Division of Hematology & Oncology
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Amy DePue, MSN, RN, OCN, CBCN*
Oncology Nurse Navigator
UNC Healthcare
Chapel Hill, NC
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Benyam Muluneh, PharmD, BCOP, CPP*
Assistant Professor, Division of Pharmacotherapy & Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy
Associate Member, Cancer Prevention and Control Program, University of North Carolina Lineberger Comprehensive Cancer Center Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Julia Rodriguez-O'Donnell, LCSW, OSW-C*
Oncology Social Worker
UNC Healthcare
Chapel Hill, NC
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
*Planning Committee
Peer Reviewers' Disclosures
Jayne Gurtler, MD
Oncologist, LCMC Health
STO Director of CME
New Orleans, LA
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Accredited Provider Disclosures
Staff Planning Committee
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Stacy Atkinson, MS, CMP, CHCP
Associate Director, Educational Initiatives
Montefiore Medical Center, Albert Einstein College of Medicine
Center for Continuing Professional Development
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Society for Translational Oncology, Durham, NC
Ann Murphy, PhD
Executive Director, Society for Translational Oncology
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Karen Eldridge, MEd
Director of Programs and Compliance, Society for Translational Oncology
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Matthew Kenney, BFA
Director of Digital Content, Society for Translational Oncology
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Sharon Lee, MS
Director of Communications and Partnerships, Society for Translational Oncology
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Ann Miller, BA
Director of Finance and HR, Society for Translational Oncology
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Collaborator Disclosures
Staff Planning Committee
AXDEV Global Inc., Virginia Beach, VA
Monica Augustyniak, MA
Researcher, AXDEV Global Inc.
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Ginny Jacobs, MEd, MLS, CHCP, FSACME
Director, Strategy and Performance, AXDEV Global Inc.
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Patrice Lazure, MSc
Director of Research, AXDEV Global Inc.
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Pam McFadden, FACEHP
Vice President, Strategy and Performance, AXDEV Global Inc.
Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Conflict of Interest Disclosure Policy
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, STO requires that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies*. STO mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, STO seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. STO is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
In accordance with the policy of STO, all persons in a position to control the content of a CME activity, including planners, faculty, authors, writers and reviewers, must disclose all financial relationships with ineligible companies* occurring within the last 24 months. STO abides by a policy of anonymous peer review: disclosure of any financial relationships with ineligible companies will be reviewed by CME program staff, the Director of CME and STO Education Council with the ad hoc assistance of external peer reviewers. All relevant financial relationships will be mitigated according to their role and prior to their involvement in the activity.
The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.
*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosure of Unlabeled Use
The Albert Einstein College of Medicine-Montefiore Medical Center and the Society for Translational Oncology (STO) require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States.
